Tucatinib gains a maintenance indication for advanced HER2-positive breast cancer
FDA approved tucatinib with trastuzumab and pertuzumab after induction treatment for advanced HER2-positive breast cancer; the trial delayed progression, while overall-survival data remain immature.
On October 7, FDA expanded the maintenance options for adults with unresectable locally advanced or metastatic HER2-positive breast cancer after induction treatment.
Tucatinib is added to trastuzumab and pertuzumab. The new decision concerns treatment after an initial regimen; it is not a new indication for every person with HER2-positive disease. [1]
HER2CLIMB-05 randomized 654 adults whose disease had not progressed after induction. Median progression-free survival was 24.9 months with tucatinib and 16.3 months with placebo, each on the same antibody backbone. The 8.6-month difference between medians describes the trial groups; it does not promise that much extra time to an individual, nor establish longer overall survival. Those survival data were not mature. [1][3]
The trade-off belongs in the decision. FDA identifies a boxed liver-toxicity warning and diarrhea precautions. In an OncLive interview, Mayo Clinic oncologist and trial coauthor Ciara O’Sullivan cautioned that some patients do well on the antibody regimen alone and do not necessarily need escalation. For an eligible patient, ask how the progression benefit, liver monitoring and added side effects fit their own treatment history. [1][2][3]
Sources & details 3 sources
Discuss in your voice app
Take the reporting, visual explanations and original sources into a conversation. Copy the brief, paste it into your preferred assistant, then start its voice mode.
Paste the brief into your voice app to discuss this reporting.Revised 9 October 2026. Copy edited 9 October to remove commentary about graphic design; reported claims, qualifications and source dates preserved.
Reporting sources
- FDA · October 7 approval and trial assessment
Original notice reopened after the barrier: indication, 654-adult trial, common antibody backbone, medians and immature overall-survival data; hepatotoxicity boxed warning checked.
- OncLive · October 7, with Mayo Clinic interview
Original specialist interview with trial coauthor Ciara O’Sullivan on who may need escalation. Separate editorial reporting provides treatment context; the interview is not an independent replication of HER2CLIMB-05.
- Diéras et al. · HER2CLIMB-05, online December 10, 2025
Original full trial paper reopened after the barrier; printed June 10, 2026. Methods, medians, immature overall survival, Seagen/Pfizer support and O’Sullivan’s coauthorship checked. Older evidence supports the October 7 approval; no fresh trial is implied.
Images & figures
Blue HER2 crosses the grey cell membrane: outside the cell above, inside below. Pink/red trastuzumab binds outside. PDB-101, April 2022; molecular context for the combination, not tucatinib or a treatment result.
Sol De Leon Cruz, Amber Herrod, Katherine H. Park and Amy Wu Wu; David S. Goodsell and Stephen K. Burley / RCSB Protein Data Bank · Source · CC BY 4.0
After qualifying induction, compare both groups on the same month scale.
Euangelion · original explanatory graphic · Source · Usage terms · Download figure